Our Pipeline

Research and Development

Developing transformative therapies begins with our personal investment in the lives of people our medicines help wherever they are in their journey, from diagnosis through ongoing care. At Horizon, we aim to make a powerful difference for our patients, their caregivers and physicians through research of breakthrough medicines as well as exploration of new applications for existing medicines. Our long-term strategy focuses on building a pipeline of clinically meaningful development-stage medicines in order to bring new options forward for people living with rare and rheumatic diseases.

Pipeline

Rare Diseases

MEDICINE / CANDIDATE
PHASE
+
HZN-001 (teprotumumab)
  • OPTIC trial: Phase 3
  • OPTIC-X trial: Phase 3 extension
PHASE 3

HZN-001 (teprotumumab) is a fully human monoclonal antibody, insulin-like growth factor-1 receptor (IGF-1R) inhibitor being studied in a confirmatory Phase 3 clinical trial for the treatment of active thyroid eye disease (TED). Teprotumumab has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration.

In patients with active TED, IGF-1R is overexpressed on orbital fibroblasts, resulting in local inflammation and orbital tissue expansion, which can lead to proptosis, or bulging of the eye.

For more information about TED, please visit our disease information page. For more information on teprotumumab, please visit clinicaltrials.gov.

Teprotumumab is an investigational medicine and its safety and efficacy have not been established.

Rheumatic Diseases

MEDICINE / CANDIDATE
PHASE
+
HZN-003
  • Optimized uricase and optimized PEGylation for uncontrolled gout
PRE-CLINICAL

HZN-003 is a genetically engineered uricase derivative, next generation gout biologic with optimized uricase and optimized PEGylation technology.

+
PASylated Uricase
  • Optimized uricase and PASylation for uncontrolled gout
PRE-CLINICAL

Collaboration agreement with XL-protein GmbH to identify clinical-stage product candidates that could be used to construct a next-generation gout biologic. If the collaboration agreement identifies clinical stage candidates, Horizon will have the right to license the candidates.

+
KRYSTEXXA® (pegloticase)
  • MIRROR immunomodulation study: KRYSTEXXA + methotrexate
PHASE 3b / 4

Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving KRYSTEXXA (MIRROR): Horizon Pharma-sponsored multicenter, efficacy and safety study for methotrexate co-administered with KRYSTEXXA to evaluate the impact of methotrexate weekly for one month prior to dosing with KRYSTEXXA and then throughout the 24 weeks of treatment with KRYSTEXXA.

For more information about gout, please visit our disease information page. For more information on KRYSTEXXA, please see KRYSTEXXA.com.

Recent Clinical Milestones

MEDICINE
STATUS

RAVICTI® (glycerol phenylbutyrate) Oral Liquid
  • Label expansion: birth to 2 months

Discovery Collaborations

MEDICINE / CANDIDATE
PHASE
+
Gout Discovery Collaboration
  • Exploration of novel approaches to treating gout
PRE-CLINICAL

Collaboration with HemoShear Therapeutics, LLC, to explore novel approaches to identify and validate biological targets to treat gout using HemoShear’s proprietary disease modeling platform, REVEAL-Tx™. The platform combines physiological and computational models of disease to identify novel treatment approaches. This collaboration may lead to potential clinical targets or new studies of which Horizon will have the rights to commercialize any successful candidates.


Clinical Trials

Clinical trials are an important part of the research and development process. People who participate in clinical trials play a vital role in helping physicians and investigators understand how an investigational medicine may be able to safely and effectively treat a specific disease or condition.

For a comprehensive list of current clinical trials involving Horizon medicines, please visit www.clinicaltrials.gov.

 

This information was last updated on Feb. 27, 2019.